The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Join the Hive!

Featured Stings

On the euro but out of it?

A Sting Exclusive: “Europe must be more ambitious in COP21 and lead on climate finance and sustainable development”, Green UK MEP Jean Lambert points out from Brussels

On Google antitrust case: “Let’s face it, some companies want to hurt Google and it goes as simple as that”

The EU Commission is lying to the “Right2Water” campaign

Eurozone’s central bank leadership prepares for shoddier prospects

EU and China resolve amicably solar panel trade dispute

The mother of all fights about inflation, growth and banks

Why the West supports the yen’s devaluation and Japanese over-indebtedness

Spirit unlimited

Germany loves a strong euro; the new Fiscal Councils can deliver despite the Greek chaos and a wider questioning of austerity

The EU Commission does nothing about the food retailing oligopoly

MWC 2016 LIVE: Mobile has power to tame transaction fees – PayPal CEO

A Year in China

Will Eurozone be able to repay its debts? Is a bubble forming there?

More capital and liquidity for the banks

Crimean crisis: not enough to slow down European indices

ECB reaches the boundaries of its mandate to revive the entirety of Eurozone

Industrial price dive may lead to point of no return

The sad plight of fledging doctors

IMF: The global economy keeps growing except Eurozone

The world to teach Germans to…un-German

The EU and North Korea: A Story of Underestimation

US – Russia bargain on Syria, Ukraine but EU kept out

Industrial producer prices on free fall and stagnant output

Europe again the black sheep at the G20 Finance Ministers and Central Bank Governors

Stricter rules and tougher sanctions for market manipulation and financial fraud

A Sting Exclusive: “Youth voice must be heard in climate change negotiations!”, Bérénice Jond Board Member of European Youth Forum demands from Brussels

To my Chinese friend

EU Parliament says ‘no’ to austerity budget

Eurozone’s north-south growth gap to become structural

IMF’s Lagarde indirectly cautioned Eurozone on deflation

Eurozone: Negative statistics bring deflation and recession closer

Chinese economy to raise speed and help the world grow

Can We(esterners) ever understand (the) Chinese

EU to spend €6 billion on youth employment and training futile schemes

How I met the Panda Woman

Ukraine-EU deal sees the light but there’s no defeat for Russia

EU sets ambitious targets for the Warsaw climate conference

EU-China relations under investigation?

Brussels to tear down the trade wall with Mexico as opposed to Trump’s “walls”

Sochi not far away from Ukraine

Eurozone’s credibility rock solid

Digital Single Market: New EU rules for online subscription services

Mood changes in Europe in favour of growth and jobs

Predicting two more years of economic stagnation

The European Commission to stop Buffering

ZTE @ MWC14: ZTE excels in all areas at this year’s Mobile World Congress

Bram in Colombia

A day that Berlin and Brussels would remember for a long time

Lagarde: Keep feeding the banks cut down wages and food subsidies

The IMF overstates the risks for Eurozone and downgrades the threats for the US economy

The EU Consumer Policy on the Digital Market: A Behavioral Economics View

Eurozone needs more than some decimals of growth

Is “Sustainable Development” a concept that integrates Health Literacy and Health Policy as a global health action?

EU Youth Conference concludes in Luxembourg with concrete plans on how to create real youth participation

Why the 33,000 staff European Commission did not have a real contingency plan for the refugee crisis?

EU Parliament: No EU-US trade agreement without safe data

No recovery for EU economy in sight and a Brexit can aggravate things for everyone

Greece @ MWC14: Greek-born mobile champions at MWC 2014

Eurozone: Economic sentiment-business climate to collapse without support from exports

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s